A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers
Background: The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. A prospective study was designed to assess the immunogenicity, efficacy, and safety of COVID-19 vaccination in this cohort. Methods: Pat...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/6/1017 |
| _version_ | 1827735426994012160 |
|---|---|
| author | Urska Janzic Urska Bidovec-Stojkovic Peter Korosec Katja Mohorcic Loredana Mrak Marina Caks Maja Ravnik Erik Skof Matija Rijavec |
| author_facet | Urska Janzic Urska Bidovec-Stojkovic Peter Korosec Katja Mohorcic Loredana Mrak Marina Caks Maja Ravnik Erik Skof Matija Rijavec |
| author_sort | Urska Janzic |
| collection | DOAJ |
| description | Background: The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. A prospective study was designed to assess the immunogenicity, efficacy, and safety of COVID-19 vaccination in this cohort. Methods: Patients with solid malignancies on active treatment were followed up after the primary course and booster third dose of vaccination to assess their anti-SARS-CoV-2 S1 IgG levels, efficacy in the case of SARS-CoV-2 infection, and safety. Results: Out of 125 patients receiving the primary course of vaccination, 66 patients received a booster third dose of mRNA vaccine, with a 20-fold increase in median anti-SARS-CoV-2 S1 IgG levels compared to Ab levels six months post-primary course of vaccination (<i>p</i> < 0.0001). After the booster third dose, anti-SARS-CoV-2 S1 IgG levels were comparable to healthy controls (<i>p</i> = 0.113). There was a decline in Ab levels 3 (<i>p</i> = 0.0003) and 6 months (<i>p</i> < 0.0001) post-third booster dose. No patients had either a severe disease course or a lethal outcome in the case of SARS-CoV-2 infection after the third booster dose. Conclusion: The third booster vaccination dose against COVID-19 in solid cancer patients triggers substantial immunogenicity and is safe and effective for preventing a severe COVID-19 disease course. |
| first_indexed | 2024-03-11T01:50:46Z |
| format | Article |
| id | doaj.art-261d440f6a5543cb8bf49f92756fe42e |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-11T01:50:46Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-261d440f6a5543cb8bf49f92756fe42e2023-11-18T12:58:04ZengMDPI AGVaccines2076-393X2023-05-01116101710.3390/vaccines11061017A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid CancersUrska Janzic0Urska Bidovec-Stojkovic1Peter Korosec2Katja Mohorcic3Loredana Mrak4Marina Caks5Maja Ravnik6Erik Skof7Matija Rijavec8Department of Medical Oncology, University Clinic of Respiratory and Allergic Diseases Golnik, 4204 Golnik, SloveniaLaboratory for Clinical Immunology and Molecular Genetics, University Clinic of Respiratory and Allergic Diseases Golnik, 4204 Golnik, SloveniaLaboratory for Clinical Immunology and Molecular Genetics, University Clinic of Respiratory and Allergic Diseases Golnik, 4204 Golnik, SloveniaDepartment of Medical Oncology, University Clinic of Respiratory and Allergic Diseases Golnik, 4204 Golnik, SloveniaDepartment of Medical Oncology, University Clinic of Respiratory and Allergic Diseases Golnik, 4204 Golnik, SloveniaDepartment of Oncology, University Medical Centre Maribor, 2000 Maribor, SloveniaDepartment of Oncology, University Medical Centre Maribor, 2000 Maribor, SloveniaMedical Faculty Ljubljana, University of Ljubljana, 1000 Ljubljana, SloveniaLaboratory for Clinical Immunology and Molecular Genetics, University Clinic of Respiratory and Allergic Diseases Golnik, 4204 Golnik, SloveniaBackground: The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. A prospective study was designed to assess the immunogenicity, efficacy, and safety of COVID-19 vaccination in this cohort. Methods: Patients with solid malignancies on active treatment were followed up after the primary course and booster third dose of vaccination to assess their anti-SARS-CoV-2 S1 IgG levels, efficacy in the case of SARS-CoV-2 infection, and safety. Results: Out of 125 patients receiving the primary course of vaccination, 66 patients received a booster third dose of mRNA vaccine, with a 20-fold increase in median anti-SARS-CoV-2 S1 IgG levels compared to Ab levels six months post-primary course of vaccination (<i>p</i> < 0.0001). After the booster third dose, anti-SARS-CoV-2 S1 IgG levels were comparable to healthy controls (<i>p</i> = 0.113). There was a decline in Ab levels 3 (<i>p</i> = 0.0003) and 6 months (<i>p</i> < 0.0001) post-third booster dose. No patients had either a severe disease course or a lethal outcome in the case of SARS-CoV-2 infection after the third booster dose. Conclusion: The third booster vaccination dose against COVID-19 in solid cancer patients triggers substantial immunogenicity and is safe and effective for preventing a severe COVID-19 disease course.https://www.mdpi.com/2076-393X/11/6/1017solid cancerCOVID-19 vaccinationbooster third doseimmunogenicity |
| spellingShingle | Urska Janzic Urska Bidovec-Stojkovic Peter Korosec Katja Mohorcic Loredana Mrak Marina Caks Maja Ravnik Erik Skof Matija Rijavec A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers Vaccines solid cancer COVID-19 vaccination booster third dose immunogenicity |
| title | A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers |
| title_full | A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers |
| title_fullStr | A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers |
| title_full_unstemmed | A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers |
| title_short | A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers |
| title_sort | three dose mrna covid 19 vaccine regime produces both suitable immunogenicity and satisfactory efficacy in patients with solid cancers |
| topic | solid cancer COVID-19 vaccination booster third dose immunogenicity |
| url | https://www.mdpi.com/2076-393X/11/6/1017 |
| work_keys_str_mv | AT urskajanzic athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT urskabidovecstojkovic athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT peterkorosec athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT katjamohorcic athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT loredanamrak athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT marinacaks athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT majaravnik athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT erikskof athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT matijarijavec athreedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT urskajanzic threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT urskabidovecstojkovic threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT peterkorosec threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT katjamohorcic threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT loredanamrak threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT marinacaks threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT majaravnik threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT erikskof threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers AT matijarijavec threedosemrnacovid19vaccineregimeproducesbothsuitableimmunogenicityandsatisfactoryefficacyinpatientswithsolidcancers |